15/2023・Trifork signs strategic investment agreement with Swiss digital health company Bluespace Ventures AG
Company announcement no. 15 / 2023
Schindellegi, Switzerland – 24 October 2023
Trifork signs strategic investment agreement with Swiss digital health company Bluespace Ventures AG
As referred to in company announcement no. 9 / 2022 on 16 May 2022, Trifork won a strategic tender and signed a contract with the Swiss company Bluespace Ventures AG (BSV), making Trifork the lead technology partner in providing advanced healthcare software to the Swiss market. In the second quarter of 2022, Trifork and BSV started the development of a new and modern eHealth platform called Compassana. In the second quarter of 2023, the platform went live successfully.
Trifork views this collaboration and the entrance into the Swiss market for digital health solutions as a strategic milestone. Based on three decades of experience and a portfolio of digital health solutions built in other countries, Trifork and BSV together will accelerate the digitalization of healthcare in Switzerland.
To strengthen the partnership further, and to underline Trifork’s commitment as a serious player in providing digital health solutions to the Swiss population, Trifork and BSV today signed an agreement to include Trifork as an investor in BSV. Trifork will own 14.29% of BSV and will join its Board of Directors. The completion of the final agreement is subject to approvals from relevant competition authorities, which are expected to be obtained in the fourth quarter of 2023.
“Trifork is truly committed to improving the Swiss healthcare ecosystem by digitalization as we have successfully done in Denmark since 1996. BSV consists of a group of very committed and visionary shareholders. These leading organizations possess the right mix of reach and energy to succeed with the creation and adoption of a digital platform that can span all healthcare providers, insurance companies, and patients in Switzerland”, says CEO and founder of Trifork, Jørn Larsen.
“By adding Trifork to our group of owners, we get an innovative technology provider very close to us who understands our needs and who can help us shape our development roadmap. Together, we are looking forward to setting the next milestones for our Swiss healthcare ecosystem”, says Peter Mittemeyer, CEO Bluespace Ventures.
Following the completion of the final agreement, Trifork’s investment in Bluespace Ventures will be reported as a financial asset and included in the Trifork Labs segment. Thus, the investment will not affect Trifork’s financial guidance for 2023, which was updated on 5 October in company announcement no. 14 / 2023.
For more information, please contact:
Kristian Dollerup, Head of Investor Relations
email@example.com, +41 76 561 1256
About Bluespace Ventures AG (BSV)
Bluespace Ventures AG was founded in 2021 by Medbase, Hirslanden, Groupe Mutuel, Helsana, and Swica and welcomed LUKS Group in 2023. BSV’s mission is to increase efficiency and healthcare quality in Switzerland by creating a digital ecosystem called Compassana where healthcare professionals, insurance companies, and patients can exchange information and services. Compassana is open to all actors in the Swiss health market. Compassana connects healthcare providers and promotes cooperation by means of a digital health platform, which is invisible to patients. The platform is the heart of the Compassana ecosystem and optimizes the integrated care of healthcare providers and the coordination of patient pathways. Patients can use all the advantages of Compassana via an app. It enables patients to easily orient themselves in the healthcare market and communicate with healthcare providers. Treatments and documents can be accessed quickly and viewed at any time. The platform promotes patients’ individual health and supports people in every situation to navigate their health path independently.
More info: https://www.compassana.ch
Trifork is a global NextGen IT company that develops innovative software solutions in collaboration with its customers. The company has close to 1,200 employees across 71 business units and offices in 14 countries. Trifork works in six business areas: Digital Health, FinTech, Smart Building, Cloud Operations, Cyber Protection, and Smart Enterprise. Trifork’s research and development activities take place in Trifork Labs, where the company continuously invests in and develops technology startups with clear synergies with Trifork. The Group also includes the conference brand GOTO, which runs a global tech community with more than 54 million views on YouTube and Instagram. Trifork Holding is a publicly listed company on Nasdaq Copenhagen.
More info: https://www.trifork.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.firstname.lastname@example.org
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi
ForFarmers N.V.: Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o.6.12.2023 10:30:00 CET | Press release
Lochem, 6 December 2023 Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o. Today, ForFarmers received approval from the Polish competition authority to acquire Piast Pasze Sp. z.o.o. ("Piast"). With this transaction, announced on 25 July 2023, ForFarmers/Tasomix's volume in Poland will expand by 410,000 tonnes, strengthening its position in the broiler sector in particular. Parties will work towards a closing of the acquisition. This transaction is in line with ForFarmers/Tasomix's strategic objectives to expand in the attractive Polish agricultural market. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For further information: Floor van Maaren, T: 06-29597746 Paweł Świerkula, Managing Director ForFarmers/Tasomix M + 48 510 22 00 22 • E: email@example.com About ForFarmers ForFarmers N.V. is an international organisation tha
Resultat af auktion over 1,75 pct. Danske Stat 2025 og 2,25 pct. Danske Stat 20336.12.2023 10:26:31 CET | pressemeddelelse
Bud, salg, skæringspris, pro rata og effektiv rente fremgår af nedenstående oversigt: ISINBud mio. kr. (nominelt)SalgSkæringskursPro-rataEffektiv rente, pct. p.a.99 23138 1,75% 15/11/20251.8601.10098,34100 %2,6499 24532 2,25% 15/11/2033300 300 97,80100 %2,50I alt2.1601.400 Salget bliver afviklet den 8. december 2023.